Nanwei Medical announced that in the first half of 2026, it achieved operating income of 1,728 billion yuan, an increase of 10.39% over the previous year; net profit to mother was 303 million yuan, a decrease of 16.5% over the previous year. Affected by the appreciation of RMB, foreign currency asset conversion resulted in exchange losses of RMB 83 million. Excluding this effect, net profit to mother was 373 million yuan, an increase of 16.41% over the previous year. Overseas revenue was 1,094 million yuan, accounting for 63%. R&D investment in the first half of the year was 98.2516 million yuan, accounting for 5.69% of revenue and 10% of revenue from innovative products, an increase of more than 40% over the previous year. The 2025 equity distribution was completed, with a total distribution of 187 million yuan; it is proposed to distribute a cash dividend of 5 yuan for every 10 shares.

Nanwei Medical announced that in the first half of 2026, it achieved operating income of 1,728 billion yuan, an increase of 10.39% over the previous year; net profit to mother was 303 million yuan, a decrease of 16.5% over the previous year. Affected by the appreciation of RMB, foreign currency asset conversion resulted in exchange losses of RMB 83 million. Excluding this effect, net profit to mother was 373 million yuan, an increase of 16.41% over the previous year. Overseas revenue was 1,094 million yuan, accounting for 63%. R&D investment in the first half of the year was 98.2516 million yuan, accounting for 5.69% of revenue and 10% of revenue from innovative products, an increase of more than 40% over the previous year. The 2025 equity distribution was completed, with a total distribution of 187 million yuan; it is proposed to distribute a cash dividend of 5 yuan for every 10 shares.